Amazon Basics Menthol Lozenges Add Another OTC Option for Short-Term Cough Relief
DailyMed’s updated label for AMAZON BASICS SF HONEY LEMON COUGH DROPS places a familiar ingredient back in focus: menthol 7.6 mg per lozenge. The product is positioned as an oral cough suppressant and oral anesthetic, with use limited to temporary relief of cough associated with a cold, minor throat irritation, and sore throat. It is an uncomplicated formulation on paper, but the label language matters because it defines exactly where a consumer product like this fits in bedside practice, self-care, and triage decisions.
The package is listed as a human OTC drug, and the product information identifies oral administration, an oval yellow lozenge, and a honey lemon flavor. The label also states an NDC code of 72288-245-40 and identifies Amazon as the labeler, with Bestco listed as the registrant and manufacturer. The marketing category is OTC Monograph Drug, tied to monograph citation M012. In practical terms, this keeps the product within an established regulatory pathway rather than a prescription-only framework.
Menthol’s Dual Role as Sensory Counterirritant and Local Anesthetic
Menthol remains a mainstay in cough lozenges because it does two jobs at once. By producing a cooling sensation and blunting local irritation in the mouth and throat, it can reduce the urge to cough and make swallowing or speaking less uncomfortable. The label reflects that dual action directly by naming both cough suppressant and oral anesthetic as the purpose of the product.
A single lozenge contains 7.6 mg of menthol. The formulation does not attempt to be a multi-ingredient cold remedy, and that restraint is clinically meaningful. A simpler product reduces the chance that a consumer will unintentionally duplicate therapy with additional cough-and-cold preparations, especially when the main target symptom is throat discomfort rather than systemic illness.
The inactive ingredient list is also revealing. Alongside water, the formulation includes acesulfame potassium, beta carotene, corn starch, eucalyptus oil, glycerin, isomalt, maltitol syrup, medium chain triglycerides, natural and artificial flavors, soybean oil, sucralose, and water. Several of these components are common in lozenge products because they shape texture, sweetness, stability, and palatability. The sugar-free positioning is implicit in the use of polyols and nonnutritive sweeteners rather than sucrose.
The Safety Language Draws a Clear Line Between Minor Irritation and Something More Serious
The warnings are the most clinically important part of the label. Severe sore throat, symptoms lasting more than 2 days, or sore throat accompanied by fever, headache, rash, swelling, nausea, or vomiting should prompt consultation with a doctor. Persistent cough is treated similarly: cough lasting more than 7 days, recurring cough, or cough with fever, rash, or persistent headache requires medical evaluation. The label is careful not to let a short-term symptomatic product stand in for diagnosis when the clinical picture is moving beyond an ordinary cold.
A sore mouth that does not improve in 7 days also warrants medical or dental evaluation. This is a small detail with a large clinical purpose. Oral pain and throat discomfort are common, but the persistence threshold forces attention back to infection, inflammatory disease, mucosal injury, or a dental source when symptoms fail to resolve on schedule.
The cautions before use are equally direct. Patients with persistent or chronic cough, such as cough related to smoking, asthma, or emphysema, are told to ask a doctor before using the product. The same advice applies to cough accompanied by excessive phlegm. In other words, the lozenge is not intended to suppress a cough that is serving a physiologic purpose, such as secretion clearance or signaling an untreated lower respiratory process.
One sentence in the label does a great deal of work: excess consumption may cause a laxative effect. That warning reflects the sweetener system, not the menthol itself, and it is a reminder that “sugar-free” does not mean symptom-free if the product is overused. The label also advises users not to take the product if the bag is torn or open, a standard packaging integrity precaution that still deserves explicit attention.
Dosing Is Simple, but the Age Cutoff Still Matters
The directions are straightforward. Adults and children 5 years and over should dissolve one lozenge slowly in the mouth and may repeat every 2 hours as needed or as directed by a doctor. Children under 5 years should ask a doctor before use. That age cutoff is important because lozenges introduce a choking risk in younger children, and the label keeps the decision in clinician hands rather than leaving it to parental guesswork.
Pregnant or breast-feeding patients are told to ask a health professional before use. The label does not provide a safety narrative beyond that instruction, so any clinical recommendation has to stay within the boundaries of the product’s own guidance. This is standard for many OTC labels, where the manufacturer provides caution rather than an expanded risk-benefit analysis.
What the Product Is, and What It Is Not
This label describes a symptom-relief product, not a treatment for the underlying cause of cough or sore throat. That distinction is central. A menthol lozenge can ease discomfort while a self-limited viral illness runs its course, but it does not resolve bacterial infection, asthma, chronic bronchitis, reflux-related throat symptoms, or allergic disease. The label’s repeated triggers for medical consultation are there to prevent a temporary analgesic effect from obscuring the need for proper workup.
The product characteristics and packaging details add another layer of traceability. The lozenge is described as yellow, oval, and 17 mm in size, with a honey lemon flavor and an imprint code of B. Packaging is listed as 140 lozenges in one bag, and the marketing start date is October 14, 2026. These are administrative details, yet they matter in pharmacy operations, supply chain review, and product identification when patients bring a package to a clinician or pharmacist for clarification.
In the end, the updated label reads like a concise reminder of how OTC respiratory symptom products should function: narrow indication, simple dosing, explicit stopping rules, and clear thresholds for escalation. When a cough persists, recurs, or comes with systemic symptoms, the lozenge is no longer the point.
What remains on the clinician’s side is the familiar task of separating transient throat irritation from disease that needs diagnosis, not just suppression.